Boris Johnson to consider legalising psilocybin

October 20, 2021

The Prime Minister of the United Kingdom, Boris Johnson, has said he will examine the latest advice on the legalisation of psilocybin, the main psychedelic compound found in magic mushrooms.

Conservative MP Crispin Blunt urged the PM to “cut through the current barriers to research into psilocybin” during a session of Prime Ministers Questions today. Mr Blunt told Johnson the drug had “exciting potential” for the treatment of mental health conditions such as depression, trauma and addiction.

Psilocybin is currently listed in Schedule 1 of the Misuse of Drugs Act, along with drugs such as MDMA and LSD. This means it cannot be lawfully possessed or prescribed and a Home Office licence is needed for use in research.

However, campaigners believe it should be moved to Schedule 2 which would place it in the same category as medical cannabis, which was legalised in 2018.

In response, the PM said “I can say that we will consider the Advisory Council on the Misuse of Drugs recent advice on reducing barriers to research with controlled drugs such as the one he describes, and we will be getting back to him as soon as possible.”

The clinical potential of psilocybin has been subject to a new wave of research in recent years. A recent medical trial carried out by researchers at the Centre for Psychedelic Research at Imperial College London found it to be “at least as effective as a leading antidepressant medication in a therapeutic setting.”

In June this year a YouGov survey, commissioned by Drug Science, found that only 13% of adults in the UK did not support psilocybin-assisted therapy.

By rescheduling psilocybin into schedule 2, the UK could become a world leader in psychedelic research. “Schedule 1 restrictions hinder our efforts whilst being unlikely to provide any meaningful reduction in the risk of diversion, when compared to Schedule 2 restrictions. The UK has an internationally recognised reputation in developing new treatments. We have an opportunity to be world leaders here as well, if the government acts to reclassify those treatments that are showing therapeutic promise into Schedule 2” said Dr James Rucker, Head of the Psychedelic Trials Group at King’s College London.





Also in Education

Owning Guns is a Constitutional Right, Unless You’re a Cannabis User

September 28, 2022

Take two of the most hot-button, tendentious issues of our time – cannabis use and gun rights – combine them, and now we really have a debate. As the law currently stands, medical cannabis patients are not afforded their 2nd amendment right to bear arms. Technically, all cannabis consumers are banned from buying guns, but only medical […]

The post Owning Guns is a Constitutional Right, Unless You’re a Cannabis User appeared first on Cannadelics.

Continue Reading

Cannabis policy changes in Africa are welcome. But small producers are the losers

September 28, 2022

TESTSTSARDSAR

Cannabis policy changes in Africa are welcome. But small producers are the losers by Clemence Rusenga

Cannabis is a drug crop with a long history in Africa. Alongside coca and opium poppy, it has been subjected to international control for nearly a century. The International Opium Convention of 1925 institutionalised the international control system and extended the scope of control to cannabis. In 1961 a new international convention was adopted to […]

A link to your site, with your site's name and description as anchor text.

Continue Reading

University of Sydney to Offer Free Cannabis Testing

September 27, 2022

TESTSTSARDSAR

University of Sydney to Offer Free Cannabis Testing by Johnny Green

The University of Sydney is launching a fairly robust study in an attempt to, as the university describes it, “investigate cannabis consumption, behaviours, and attitudes among users.” Part of the study involves offering free, anonymous cannabis testing for people that cultivate their own cannabis in the Australian Capital Territory (ACT). Cannabis was decriminalized in 2020 in the […]

A link to your site, with your site's name and description as anchor text.

Continue Reading